Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v18-EN | Version v8-EN | |
---|---|---|
Language | English | English |
Date Updated | 2022-09-28 | 2022-07-22 |
Drug Identification Number | 02247938 | 02247938 |
Brand name | VASOPRESSIN INJECTION USP | VASOPRESSIN INJECTION USP |
Common or Proper name | VASOPRESSIN | VASOPRESSIN |
Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
Ingredients | VASOPRESSIN | VASOPRESSIN |
Strength(s) | 20UNIT | 20UNIT |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR |
Packaging size | 5ML 1LIVI | 5ML 1LIVI |
ATC code | H01BA | H01BA |
ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
Anticipated start date | 2022-03-04 | |
Actual start date | 2022-08-18 | |
Estimated end date | 2022-09-30 | 2022-10-07 |
Actual end date | 2022-09-27 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | ||
Health Canada comments |